Palvella Therapeutics, Inc. (PVLA) Stock Ticker
PVLA right now
Market factors today
Unlock the full PVLA picture
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
PVLA stock facts
| Ticker symbol | PVLA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.0B |
| CEO | Wesley H. Kaupinen |
| Employees | 29 |
| Headquarters | Wayne, PA, US |
| IPO date | 2015-01-02 |
| Website | palvellatx.com |
What you can see for PVLA on Tickr
Live PVLA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PVLA report.
Rankings
FAQ
What is the ticker symbol for Palvella Therapeutics, Inc.?
The ticker symbol for Palvella Therapeutics, Inc. is PVLA, listed on the NASDAQ Global Market.
What is PVLA?
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for…